AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021
Feb 26, 2021
29864_dirs_2021-02-26_d6f3b5a1-8b92-4187-bdbf-2bf156edd97f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-02-24
Reporting Person: Silva Paul M (SVP & Chief Accounting Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-24 | Common Stock | F | 864 | $217.57 | Disposed | 15964 | Direct |
| 2021-02-25 | Common Stock | S | 244 | $211.80 | Disposed | 15720 | Direct |
| 2021-02-25 | Common Stock | S | 452 | $213.12 | Disposed | 15268 | Direct |
| 2021-02-25 | Common Stock | S | 258 | $214.32 | Disposed | 15010 | Direct |
| 2021-02-25 | Common Stock | S | 126 | $216.25 | Disposed | 14884 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 169 | Indirect |
Footnotes
F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $211.80 (range $211.57 to $212.07).
F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $213.12 (range $212.82 to $213.79).
F5: Open market sales reported on this line occurred at a weighted average price of $214.32 (range $213.90 to $214.69).
F6: Open market sales reported on this line occurred at a weighted average price of $216.25 (range $215.79 to $216.76).